The effect of different concentrations of lactose powder on the airway function of adult asthmatics  by THOREN, P. et al.
Vol.95 (2001) 870^875The e¡ect of di¡erent concentrations of lactose
powder on the airway function of adult asthmatics
P.THOREN*, A.WALLIN{, P. J.WHITEHEAD{, ANDT. SANDSTROº M{
*Department of Internal Medicine, Lycksele Hospital, Lycksele, Sweden, {Department of Respiratory Medicine and
Allergy,University Hospital,Umeaî , Sweden and
{RespiratoryTherapeutic Development,GlaxoWellcome R&D,
Stockley Park,U.K.
Abstract Lactose is widely used as a carrier of drugs in inhalation devices for asthmatic patients, but some clinicans
have suspectedthat itmaycause bronchoconstriction.Onlya few studieshavebeendoneto examinethis andtheresults
arenotuniform.This studywas conducted to determine the e¡ects of inhalationgrade lactose deliveredby DiskhalerTM
on lung function and airwayconductance in asthmatic subjects.The e¡ectof ¢ve doses of lactose ranging from 6?25mg
to 100mg and placebo were investigated using spirometry and constant volume plethysmography. Nineteen subjects
(nine females) with stable asthma and a proven reversibility of at least 12% in forced expiratory volume in 1 sec (FEV1)
(compared to baseline) in the last 6 months, were included in this single-centre, randomized, placebo-controlled, dou-
ble-blind, cross-over study.The subjects received placebo plus ¢ve doses of lactose on one study day and six doses of
placebo on another study day. Both doses and study days were assigned in a random order, and intervals of 1h were
allowed between each dose and at least 36 h between study days. Speci¢c airways conductance (sGaw) and FEV1were
measured periodically over the course of1h after each dose of lactose or placebo. Administration of lactose at four or
eight times the concentration in the DiskusTM and DiskhalerTM dry powder inhalers did not result in any statistically sig-
ni¢cantchangesin FEV1. sGawalso showedno statisticaldi¡erencebetweenlactose andplaceboat1or 3minpost-dosing.
Both placebo and lactose produced both dilatation and constriction of the airways in the same patients, with no consis-
tency in direction and no dose^response relationship.No adverse e¡ect of lactose on airways conductance or FEV1of
stable asthmatic patientswas found inthis studywhen given at higher thannormal clinical doses.
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Dry powder inhalers (DPI) have been introduced to help
overcome the co-ordination problems experienced by
some patients using pressurized metered dose inhalers
(MDIs). Most DPIs are breath-actuated devices which
relyon thepatient’s inhalation to dispense a dose of drug,
the e⁄ciency of their delivery depending on the inhala-
tion manoeuvre, the design of the inhaler and the
formulation of the inhalation powder (1).Because themi-
cronizeddrugparticles in drypowders arevery cohesive
and have poor £ow properties they are generally
mixed with larger inert carrier particles, most com-Received 28 December 2000, accepted in revised form13 June 2001and
published online13 September 2001
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Thomas.sandstrom@lung.umu.semonly lactose, to make the powder blend less cohesive
andmore free-£owing (2).This helps to ensure accurate
dosing as small amounts of drug can be measured into
individual factory dispensed doses, and also improves
the emptying of themicronizedmaterials from the deliv-
ery system (3,4).During inhalation the drug particles are
separated from the surface of the carrier particlesby the
energy of the inspired air£ow.
Lactose ful¢ls many of the requirements of an ideal
carrier, being readily available in a pharmaceutical grade,
chemically and physically stable, and inert to most drug
substances (5).Other carriers used include trehalose and
manitol, which are sugar structures similar to lactose (6).
Another important requirement for an ideal carrier is
that it should be readily cleared from the airways and
have no harmful e¡ects on the respiratory tract: little is
known about the e¡ect of inhaled lactose on airways
function, however. It hasbeen suggested fromin vitrodata
that lactose may cause in£ammation and mucus
*DiskusTM,DiskhalerTM and RotadiskTM are trademarks of the
GlaxoSmithKline group of companies.
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have reported irritation and chest tightness after inhala-
tion of drypowder (8).Data from two studies speci¢cally
to investigate the e¡ects of inhaling lactose have shown
con£icting results, however.One showed that inhalation
of a total dose of 600mg of lactose over 20min showed
little bronchoconstrictor or irritant e¡ect on the air-
ways of asthmatic subjects (9), while the other (uncon-
trolled) study found that 25mg lactose caused a
signi¢cant decrease in airways conductance 1^3min
post-dosing (8). This study was therefore designed to
investigate the e¡ect of di¡erent concentrations of lac-
tose on pulmonary function in stable asthmatic subjects,
in a double blind, placebo-controlled manner. Airway
function was assessed by forced expiratory volume in 1
sec (FEV1) obtained by spirometry, and speci¢c airways
resistance and conductance measurements, obtained by
constant volume plethysmography.
METHODS
Patients
Nineteen subjects aged 18^57 years with a history of
asthmawere randomized from 20 subjects screened. At
screening all patients had to either have a documented
history of reversibility 12% in FEV1 [or 20% peak
expiratory £ow (PEF)] within the previous 6 months, or
demonstrate similar reversibility to 800mg of salbutamol
after withholding bronchodilator for6h. Patients who
were receiving short-acting b2-agonists as required and
were able to use the DiskhalerTM correctly were
included. All study subjects were symptom-free at the
pre-study visit: one had wheezing on forced expiration.
Patientswhohadexperiencedanexacerbation of asthma
and required a change in their usual asthma medication,
required either oral steroids or antibiotics, or had been
hospitalized for their respiratory diseasewithin 4 weeks
of the screening visit, were excluded. Also excluded
were patients who had used long-acting b2-agonists
within 2 weeks of the screening visit, who smoked420
cigarettes a day regularly or had a smoking history of 20
pack-years, werepregnant or lactating, hadknown intol-
erance to lactose, or had clinical or laboratory evidence
of serious uncontrolled systemic disease.
Study design
This was a single-centre, randomized, double-blind,
placebo-controlled, cross-over study. There were three
study visits: a pre-study visit to assess eligibility and two
study days on which treatments were administered.On
one study day patients received lactose or placebo
(emptyblisters) on sixoccasions,while on the other they
received sixdoses of placebo.The order of the studydays
wasrandomized and, to avoid anycarry-over e¡ect, theywere separated by at least 36h. The doses of lactose
administered were 6?25mg, 12?5mg, 25mg, 50mg and
100mg, representing doses up to eight times that used
clinically in a DiskusTM*, or four times that in a Diskha-
lerTM*.We think these doses represent the highest likely
to be taken at one time by patients in a clinical situation,
and they are equivalent to themaximumdosedeliverable
from one four-place RotadiskTM*. Each study dose was
separated by1h from the previous one and the order of
doses was randomized.
On a study day, each patient was given a treatment
packconsisting of six four-place DiskhalersTM pre-loaded
with RotadisksTM containing di¡erent doses of lactose or
placebo.Therewas nomore than 25mg inhalation grade
lactose powder in each blister (the dose present in com-
mercial RotadiskTM blisters). The six di¡erent Rota-
disksTM were as follows:
Four placebo (empty) blisters;
One lactose 6?25mg blister and three placebo blisters;
One lactose12?5mg blister and three placebo blisters;
One lactose 25mg blister and three placebo blisters;
Two lactose 25mg blisters and two placebo blisters;
Four lactose 25mg blisters.
Doses were administered by taking all four blisters of
a RotadiskTM in quick succession, the timing of the lung
function assessments being measured from the point
that the last blister was inhaled.On the placebo day all
DiskhalersTM were loaded with placebo RotadisksTM
(empty blisters); this was included to control for any
e¡ect due to non-lactose factors such as bronchocon-
striction due to rapid inspiration of ambient air. Patients
were asked to avoid ca¡eine during study days and for at
least 6 h beforehand.The use of short acting b2-agonists
within 6h before a visit was also not permitted.
Ethics
Ethics Committee and Regulatory Authority approvals
were both obtained prior to commencement of the
study, and all patients gave their written informed con-
sent to participate in the study before entry.
Measurement of lung function
Airway calibre was assessed by measuring speci¢c air-
ways conductance (sGaw) in a constant volume whole
body plethysmograph (‘body box’) (Master Lab Body,
Erich Jaeger GMBHA, Hoechberg, Germany). Patients
remained in the plethysmograph for each set of sGaw
readings butwere then allowed to leave it and relaxuntil
shortly before the next dosing occasion. Following base-
line assessment (t = 0), patients inhaled lactose powder
TABLE 1. Summary of demographic and clinical charac-
teristics
n (%)
Numberof patients 19
Male: female 10:9
Age (years) Mean (SD) 30?4 (9?9)
Range 18^57
Duration of asthma 51year 2 (10%)
1^510 years 5 (27%)
10 years 12 (63%)
Smoking status Current smoker 1 (5%)
Ex-smoker 7 (37%)
Never smoked 11 (58%)
FEV1reversibility at
pre-study visit (%)
(12 patients)
Mean (SD) 18 (8%)
Range 8^33
SD: standard deviation.
872 RESPIRATORYMEDICINEor placebo andmeasurementswere taken at1, 3, 5,10 and
15min afterwards. FEV1 was measured outside of the
body box at 10min before the ¢rst dose, and at 20 and
50min after each dose for all doses (the 50minmeasure-
ment acting as the710measurement for thenextdose).
Three FEV1measurementswere taken ateach timepoint
and the highest recorded.
Safety assessments
These comprised the recording of clinical adverse events
throughout the study, and of baseline pulmonary auscul-
tation and vital signs (pulse rate and blood pressure) at
visit 1 to assess suitability for the study. Patients were
asked how they felt and have their lung function moni-
tored throughout the two study days. Patients with a
known hypersensitivity to lactose were excluded from
the study.
Statisticalmethods
Sample size
There was insu⁄cient published data to allow a proper
sample size calculation to be made. Our previous study
(8) had demonstrated signi¢cant ¢ndings with 15
patients, so the sample size in this study was based on
practical rather than statistical considerations, with the
aim of recruiting 20 patients to get18 randomized.
E⁄cacyanalysis
The FEV1 recorded 10min prior to dosing was taken as
the baseline value for each dose, and the one at 20min
after dosing represented the post-dosing value. Results
were summarized using summary statistics (n, mean,
standard deviation, minimum and maximum) and the
percentage change from baseline was calculated. The
percentage change frombaselinewas analysedusing ana-
lysis of covariance with the subject identi¢er, study day
(1st or 2nd), dosing order from 1st to 6th dose and the
baseline value included as covariates.
For sGaw the baseline was taken as the measurement
immediatelyprior to dosing (t=0), and themeasurements
to be analysedweremade at1and 3min after dosing.The
analysis was the same as for FEV1. Measurements after
3min were not analysed statistically so as to minimize
the number of comparisons and preserve the power of
the study: our previous study (8) suggested that any
changes in sGaw wouldbe seen in the ¢rst 3min.Thedata
were, however, available to allow the duration of any ef-
fects to be determined.
All concentrations of lactosewere compared toplacebo.
For the statistical comparison, the seven sets of placebo
measurements for each subject (six from theplacebo day
and one from the lactose day) were all included in each
analysis.RESULTS
Twenty patients were recruited into the study, of
whom19 ful¢lled the inclusion criteria and were rando-
mized, and received at least one dose of study
medication.One patient was withdrawn after randomi-
zation due to an exacerbation of asthma after attending
one study day (placebo only), otherwise all randomized
patients completed all study procedures and assess-
ments.Eightof thepatientswere currentor ex-smokers,
with a mean history of 5?1pack-years (maximum15 pack-
years). The demographic details of the patients are
shown inTable1.
E⁄cacy
FEV1
Inhaling placebo resulted in an increase in FEV1of 2?22%
at 20min post-dosing compared to the pre-dosing
value. By comparison, lactose at the lowest concentra-
tion (6?25mg) resulted in a 1?95% increase in FEV1
(Fig. 1; Table 2). Higher concentrations of lactose:
12?5mg, 25mg, 50mg and100mg, resulted in changes in
FEV1 of 0?24%, 2?96%, 0?5% and 70?7%, respectively.
Therewas no evidence of a trend in changes in FEV1with
increasing lactose dose and there were no statistically
signi¢cant di¡erences between any dose of lactose and
placebo (Table 2).The adjustedmean di¡erence between
lactose and placebo varied between 72?2% (100mg
dose) and +1?8% (25mg dose), and therewere no statis-
tically signi¢cantdi¡erences between any dose of lactose
and placebo.
sGaw
TABLE 2. Summaryof FEV120minpost-dosing
Change frompre-dosing in FEV1 (%)
Placebo 6?25mg 12?5mg 25mg 50mg 100mg
Mean 2?22 1?95 0?24 2?96 0?5 70?7
SD 2?78 4?68 2?82 5?73 3?2 2?62
Lactose vs. placebo*
Adjustedmean di¡erence 0?7 71?0 1?8 70?8 72?2
SE 1?2 1?2 1?2 1?2 1?2
95% Cl 71?65, 3?04 73?35,1?34 70?59,4?10 73?13,1?55 74?49,0?19
P-value 0?561 0?398 0?141 0?508 0?072
*ANCOVAonthe % change frompre-dosingwith covariates of patient, studyday, time andbaseline FEV1included.
Fig. 1. Mean FEV1pre- (&) and 20minpost-dosing ( ).
Fig. 2. Mean percentage change (+SD) from pre-dosing in
sGaw after1min (&) and 3min ( ).
TABLE 3 Summaryof sGaw1minpost-dosing
% change frompre-dosing in sGaw
Placebo 6?25mg 12?5mg 25mg 50mg 100mg
Mean 73?24 72?96 76?65 0?87 78?30 73?31
SD 7?18 11?09 11?89 12?14 10?32 14?84
Lactose vs. placebo*
Adjustedmean di¡erence 0?6 73?1 4?3 75?0 0?0
SE 2?7 2?7 2?7 2?7 2?7
95% Cl 74?77,6?04 78?53, 2?28 71?15,9?66 710?36,0?45 75?36, 5?45
P-value 0?818 0?255 0?122 0?072 0?988
*ANCOVAonthe % change frompre-dosingwith covariates of patient, studyday, time andbaseline sGaw included.
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cally relevant, bronchoconstriction, re£ected by a
decrease of 73?24% at 1min post-dosing compared
to pre-dosing levels. Changes after lactose ranged
between 78?30% (50mg dose) and +0?87% (25mgdose) at this time point. There was no evidence of a
trend in changes with increasing lactose dose, and there
were no statistically signi¢cant di¡erences between
any dose of lactose and placebo (Fig. 2; Table 3). At
3min post-dosing inhaling placebo resulted in a increase
of 3?33% when compared to pre-dosing levels, and
changes after lactose ranging between 70?25%
{TurbuhalerTM is a trademark of Astrazeneca.
{EasyhalerTM is a trademark of Orion Pharma.
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to pre-dosing. There was no evidence of any trend
with increasing lactose dose and there were no
statistically signi¢cant di¡erences between any dose of
lactose and placebo. The adjusted mean di¡erence be-
tween lactose and placebo varied between 75?0%
(50mg dose) and +4?3% (25mg dose) at 1min post-
dosing, and there were no statistically signi¢cant di¡er-
ences between any dose of lactose and placebo nor
dose-related trend. The data at 3min showed a similar
lack of statistical signi¢cance and trend, and smaller dif-
ferences than at1min.
Safety
Only one adverse event was reported during the study:
an exacerbation of asthma which occurred 5 days after
the patient had attended their ¢rst study day and
received placebo only. The event was assessed as not
related to the study drug and the patient was subse-
quently withdrawn from the study. No serious adverse
events were reported.
DISCUSSION
There is little published data on the e¡ect of lactose on
airways function as opposed to its e¡ects onpatient pre-
ference or dosing perception.One study in10 asthmatics
with known bronchial hyper-responsiveness to metha-
choline (9) found little or no e¡ect on FEV1 of 600mg
lactose administered over 20min with the authors con-
cluding that themajorityof thebronchoconstrictionwas
due to the forced expiratory volumemanoeuvre itself. In
ourprevious study in15 asthmaticswith FEV1reversibility
415% (8), however, we found a signi¢cant reduction in
speci¢c airways conductance (sGaw) 1^3min after 25mg
lactose and concluded that lactose could cause broncho-
constriction in asthmatics. Our previous study, though,
was uncontrolled, and so we set out to examine both
FEV1and sGaw over a range of doses of lactose in a dou-
ble-blind, placebo-controlled study.
For FEV1we found only small variations after inhaling
empty blisters (placebo) or lactose, and no statistically
signi¢cant di¡erences between lactose and placebo.The
changes we saw probably represent the natural variabil-
ity of the measurement, therefore, and we concurred
with the results of Shaw et al. (9) by failing to ¢nd any
clinically relevant reduction in FEV1.
The plethysmography data supported the conclusions
from the FEV1 results. sGaw at 1 and 3min after inhaling
again showed variable small changes not apparently re-
lated to lactose dose, and did not show any statistically
signi¢cant di¡erences between lactose and placebo.
Our previous study, where we found a signi¢cant
e¡ect of 25mg lactose on sGaw (8), was a smaller, openlabel studyusingonly a single dose of lactose andnoempty
blisters for control. In addition, the subjects had a rever-
sibility 415% at baseline and were symptomatic, com-
pared with a proven reversibility of 412% in the last 6
months and stable asthma for those in the current study.
The decrease of sGaw after lactose at 1 and 3 min in
ourprevious studycould simplyhavebeen a consequence
of the inspiratorymanoeuvre itself in thosemore symp-
tomatic subjects or of being ‘locked in’ the bodybox, and
hence unrelated to the presence of lactose. In the pre-
sent study we controlled for these factorsby administer-
ing placebo blisters, and did not detect any signi¢cant
decrease from baseline at 1 or 3min or di¡erences
between lactose and placebo. Further studies of this
type would be needed to de¢nitively exclude broncho-
constriction due to lactose powder in patients with un-
stable asthma. No increase in bronchoconstriction
episodes was reported in a recent study of prednisone-
dependent severe asthmatics whose oral steroidwas re-
placed by a lactose-containing formulation (DiskusTM) of
£uticasone propionate (14), however, and their FEV1 im-
proved after the change. It is probable therefore that in
clinical situations lactose powder either exerts no e¡ect
on severe/unstable asthma, or an imperceptible one in
relation to the e¡ect of the drug given.
Concerns about the theoretical risks of lactose should
be weighed against the bene¢ts from its inclusion. Car-
riers such as lactose aid the £ow and dispersion proper-
ties of drypowder formulations, helping the deliveryof a
high ¢ne particle fraction of drug to the lung while the
carrier remains in the upper airways. This has been
shown for lactose formulations from theDiskusTM inhaler,
for example, by consistent emission of drug in the ¢ne
particle range andconsistencyof dosing close to the label
claim (10,11). Radiolabelling has shown that there is high
oropharyngeal deposition of inhaled lactose with only a
small percentage deposited in the lungs (12).
Aswell as aiding dispersion, lactose also helps patients
to perceive that theyhave taken a dose, thus aiding treat-
ment compliance (13). Indeed, some patients have com-
plained when given DPIs that deliver drug without a
lactose carrier that the devices are not working (13),
whilst a small proportion do not appreciate the taste
sensation.There are good reasons, therefore, for includ-
ing a lactose carrier in an inhaled dry powder formula-
tion so long as it is safe, and it is used in a number of
di¡erent inhalers, for example DiskusTM, DiskhalerTM,
TurbuhalerTM{ and EasyhalerTM{. To our knowledge the
highest single dose of lactose delivered by these devices
is 25mg.Our study found that lactose powder, at doses
at least four times higher than those used commercially
in inhalers, produced no evidence of any clinically
relevant changes in airway function in stable asth-
EFFECTOFLACTOSEPOWDERONAIRWAYFUNCTIONINASTHMATICS 875matics, and so is probably safe for use in this patient
group.
In summary, this study showed that high con-
centrations of lactose were not associated with any
clinically important changes in FEV1 or airway conduc-
tance in stable asthmatic subjects.No statistically signi¢-
cant di¡erence from placebo was observed. The
small changes seen showed no consistency in direction
and no dose^response relationship, and are likely to
be attributable to the subject variation and measure-
ment techniques. More work needs to be done to con-
¢rm its safety in other parameters. Lactose is therefore
not only a useful additive in dry powder inhalers, with
regards to FEV1 and airways conductance, it is probably
also a safe one.
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